首页> 外文期刊>FEBS Letters >Lectin‐like oxidized low density lipoprotein receptor‐1 (LOX‐1) serves as an endothelial receptor for advanced glycation end products (AGE)
【24h】

Lectin‐like oxidized low density lipoprotein receptor‐1 (LOX‐1) serves as an endothelial receptor for advanced glycation end products (AGE)

机译:类似于凝集素的氧化型低密度脂蛋白受体-1(LOX-1)作为晚期糖基化终末产物(AGE)的内皮受体

获取原文

摘要

>Advanced glycation end products (AGE) are known to serve as ligands for the scavenger receptors such as SR-A, CD36 and SR-BI. In the current study, we examined whether AGE is recognized by lectin-like oxidized low density lipoprotein receptor-1 (LOX-1). Cellular binding experiments revealed that AGE-bovine serum albumin (AGE-BSA) showed the specific binding to CHO cells overexpressing bovine LOX-1 (BLOX-1), which was effectively suppressed by an anti-BLOX-1 antibody. Cultured bovine aortic endothelial cells also showed the specific binding for AGE-BSA, which was suppressed by 67% by the anti-BLOX-1 antibody. Thus, LOX-1 is identified as a novel endothelial receptor for AGE.
机译:已知高级糖基化终产物(AGE)可用作清道夫受体(例如SR-A,CD36和SR-BI)的配体。在当前的研究中,我们检查了AGE是否被凝集素样氧化的低密度脂蛋白受体-1(LOX-1)识别。细胞结合实验表明,AGE-牛血清白蛋白(AGE-BSA)显示出与过表达牛LOX-1(BLOX-1)的CHO细胞的特异性结合,这种结合可被抗BLOX-1抗体有效抑制。培养的牛主动脉内皮细胞也显示出对AGE-BSA的特异性结合,该结合被抗BLOX-1抗体抑制了67%。因此,LOX-1被鉴定为AGE的新型内皮受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号